BRPI0516803A - oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos - Google Patents

oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos

Info

Publication number
BRPI0516803A
BRPI0516803A BRPI0516803-1A BRPI0516803A BRPI0516803A BR PI0516803 A BRPI0516803 A BR PI0516803A BR PI0516803 A BRPI0516803 A BR PI0516803A BR PI0516803 A BRPI0516803 A BR PI0516803A
Authority
BR
Brazil
Prior art keywords
oxylipines
dpan
production
derived
long chain
Prior art date
Application number
BRPI0516803-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Linda Mary Arterburn
James Flatt
Jung Lee
Elswyk Mary Van
William Barclay
Bindi Dangi
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Publication of BRPI0516803A publication Critical patent/BRPI0516803A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0516803-1A 2004-11-19 2005-11-21 oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos BRPI0516803A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62984204P 2004-11-19 2004-11-19
US72903805P 2005-10-21 2005-10-21
PCT/US2005/042462 WO2006055965A2 (en) 2004-11-19 2005-11-21 Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Publications (1)

Publication Number Publication Date
BRPI0516803A true BRPI0516803A (pt) 2008-09-23

Family

ID=36407879

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516803-1A BRPI0516803A (pt) 2004-11-19 2005-11-21 oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos

Country Status (13)

Country Link
US (2) US7884131B2 (enExample)
EP (1) EP1824809A4 (enExample)
JP (1) JP2008520739A (enExample)
KR (1) KR20070090928A (enExample)
CN (1) CN101102988B (enExample)
AU (1) AU2005306320B2 (enExample)
BR (1) BRPI0516803A (enExample)
CA (1) CA2588166A1 (enExample)
EA (1) EA010802B1 (enExample)
IL (1) IL183246A0 (enExample)
MX (1) MX2007006049A (enExample)
NZ (1) NZ555394A (enExample)
WO (1) WO2006055965A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
MX336435B (es) * 2005-07-08 2016-01-19 Dsm Ip Assets Bv Acidos grasos poliinsaturados para el tratamiento de demencia y condiciones relacionadas con pre-demencia.
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007090162A2 (en) * 2006-01-31 2007-08-09 Martek Biosciences Corporation OXYLIPINS FROM STEARIDONIC ACID AND γ-LINOLENIC ACID AND METHODS OF MAKING AND USING THE SAME
GB0604647D0 (en) 2006-03-08 2006-04-19 Shchepinov Mikhail Stabilized food supplements and their derivatives
CA2650607A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
WO2008011085A1 (en) * 2006-07-19 2008-01-24 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
US20080161274A1 (en) * 2006-10-26 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compounds and methods for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
US20110190389A1 (en) * 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
PL2124973T3 (pl) * 2007-03-23 2015-10-30 Novartis Ag Kompozycja zawierająca kwasy tłuszczowe omega-3 oraz zamaskowane lub powleczone sole miedzi
WO2008118457A2 (en) * 2007-03-26 2008-10-02 University Of Medicine And Dentistry Of Nj Synthesis of resolvins and intermediates, compounds prepared thereby, and uses thereof
US8324277B2 (en) 2007-08-01 2012-12-04 University of Pittsburgh—of the Commonwealth System of Higher Education Nitrated-fatty acids modulation of type II diabetes
CA2699483A1 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Compositions and methods for modulating immune function
KR20150115959A (ko) * 2007-10-12 2015-10-14 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
WO2009155439A2 (en) 2008-06-19 2009-12-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
US8927747B2 (en) * 2008-09-16 2015-01-06 The Brigham And Women's Hospital, Inc. 14-hydroxy-docosahexaenoic acid compounds
CA2742227C (en) * 2008-10-31 2017-01-24 Lipid Pharmaceuticals Ehf. The use of fatty acid compositions as laxatives
WO2010095706A1 (ja) * 2009-02-20 2010-08-26 国立大学法人東京大学 新規抗炎症性化合物
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
WO2010118761A1 (en) * 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
JP2013500966A (ja) * 2009-07-31 2013-01-10 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 抗炎症剤としての脂肪酸
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
SG178948A1 (en) 2009-09-01 2012-04-27 Catabasis Pharmaceuticals Inc Fatty acid niacin conjugates and their uses
US8686167B2 (en) 2009-10-02 2014-04-01 Complexa, Inc. Heteroatom containing substituted fatty acids
AU2010313249B2 (en) 2009-10-30 2016-05-19 Biojiva Llc Alleviating oxidative stress disorders with PUFA derivatives
WO2012023254A1 (ja) * 2010-08-19 2012-02-23 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
WO2012026106A1 (ja) * 2010-08-25 2012-03-01 国立大学法人 東京大学 光学活性な新規抗炎症性化合物及びその製造方法
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CA2834342C (en) 2011-04-26 2021-08-31 Retrotope, Inc. Impaired energy processing disorders and mitochondrial deficiency
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
US10154983B2 (en) 2011-04-26 2018-12-18 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating PUFAs
DK2701697T3 (da) 2011-04-26 2020-06-29 Retrotope Inc Oxidative nethindesygdomme
US9416118B2 (en) 2011-06-10 2016-08-16 The Brigham And Women's Hospital, Inc. Docosahexaenoyl ethanolamides
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
US10322118B2 (en) * 2012-04-10 2019-06-18 Trustees Of Dartmouth College Compounds and methods for inhibiting Cif virulence factor
CN110478342A (zh) 2012-05-10 2019-11-22 索卢泰克斯Na有限责任公司 含有天然专门促消退介质及其前体的具有抗炎活性的油
EP2861227A4 (en) 2012-06-17 2016-01-27 Matinas Biopharma Inc OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
AU2014205369B2 (en) 2013-01-11 2018-08-09 Massachusetts Eye And Ear Infirmary CYP450 lipid metabolites reduce inflammation and angiogenesis
WO2014130894A1 (en) * 2013-02-21 2014-08-28 University Of Southern California Compositions for the treatment of inflammatory diseases
EP2968246A4 (en) * 2013-03-13 2016-08-03 Matinas Biopharma Inc OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE
US9902681B2 (en) 2013-05-30 2018-02-27 The Brigham And Women's Hospital, Inc. N-3 immunoresolvents: structures and actions
WO2016130522A1 (en) * 2015-02-09 2016-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compounds, compositions, and methods for the treatment of inflammatory, degenerative, and neurodegenerative diseases
BR112018000254A2 (pt) 2015-07-07 2018-09-04 H Lundbeck As inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
EP3325438A4 (en) * 2015-07-20 2019-04-03 The Brigham and Women's Hospital, Inc. STRUCTURAL EXPLANATION OF NOVEL 13-SERIES RESOLVINES THAT INCREASE WITH ATORVASTATIN AND REMOVAL INFECTIONS
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用
EP3950649A1 (en) 2015-11-23 2022-02-09 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
WO2019104311A1 (en) * 2017-11-27 2019-05-31 Brown University Compositions and methods for suppressing neurological disease
WO2019104315A1 (en) * 2017-11-27 2019-05-31 Brown University Compositions and methods using lipids for treating neurological disease
WO2019203540A2 (ko) 2018-04-16 2019-10-24 한국생명공학연구원 다중불포화지방산의 멀티-하이드록시 유도체 생산 방법
HUE065709T2 (hu) 2018-05-25 2024-06-28 Cardurion Pharmaceuticals Inc 6-[(3S,4S)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropirán-4-il-7H-imidazo[1,5-a] pirazin-8-on vegyület monohidrát és kristályos formái
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR102673270B1 (ko) * 2018-10-15 2024-06-07 (주)아모레퍼시픽 피부장벽 강화용 조성물
KR102704402B1 (ko) 2018-10-24 2024-09-06 (주)아모레퍼시픽 피부장벽 강화용 조성물
CN114980973A (zh) 2019-11-12 2022-08-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
KR20220143931A (ko) 2020-02-21 2022-10-25 레트로토프 인코포레이티드 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
KR20220159751A (ko) 2021-05-26 2022-12-05 (주)아모레퍼시픽 미백용 조성물 및 이를 이용한 피부 미백방법
WO2024229108A1 (en) * 2023-05-01 2024-11-07 The Regents Of The University Of California In-situ production of anti-inflammatory lipids using milk fat globules

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63238075A (ja) * 1987-03-24 1988-10-04 Mitsumaru Kagaku Kk 高度不飽和脂肪酸からのラクトン類の製造法
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5102670A (en) 1990-09-14 1992-04-07 Abraham Nader G Method for treating eye disorders by reducing 12(r)-hydroxyeicosatetraenoic acid and 12(r)-dihydroxyeicosatrienoic acid levels
JPH05286956A (ja) * 1992-04-06 1993-11-02 Nippon Suisan Kaisha Ltd ドコサペンタエン酸モノエポキシ体、及びその製造法
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
CZ281096B6 (cs) * 1994-06-30 1996-06-12 Jindřich Mudr. Drsc. Mourek Tuková složka mléčné výživy a dětská výživa
US5955496A (en) 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates
DK0956013T3 (da) 1996-10-11 2003-08-04 Scarista Ltd Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre
US6174695B1 (en) * 1997-08-12 2001-01-16 The Regents Of The University Of California Epoxide hydrolase inhibitor methods
DE19757414A1 (de) 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
JPH11209259A (ja) * 1998-01-20 1999-08-03 Noevir Co Ltd 皮膚化粧料
ES2286999T5 (es) 1999-03-04 2016-11-17 Suntory Holdings Limited Utilización de un material que contiene ácido docosapentaenoico
EP1197560A4 (en) 1999-07-07 2005-08-03 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING HYDROXILATED FATTY ACID AND DELTA LACTONE
BR0015404A (pt) 1999-11-09 2002-06-25 Alcon Inc Compostos relacionados com ácido 15-hidroxieicosatetraenóico e métodos de uso
IL151299A0 (en) * 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
WO2002029018A2 (en) 2000-10-06 2002-04-11 Michigan State University Divinyl ether synthase gene and protein, and uses thereof
EP2255668A3 (en) * 2001-05-14 2012-04-04 Martek Biosciences Corporation Production and Use of a Polar Lipid-Rich Fraction Containing Omega-3 and/or Omega-6 Highly Unsaturated Fatty Acids from Microbes, Genetically Modified Plant Seeds and Marine Organisms
WO2003053423A2 (en) * 2001-12-18 2003-07-03 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
US7527935B2 (en) 2002-03-19 2009-05-05 Mitsubishi Tanabe Pharma Corporation G-protein coupled receptor having eicosanoid as ligand and gene thereof
SI2022775T1 (sl) 2002-04-01 2015-03-31 University Of Southern California Trihidroksi polinenasiäśeni eikosanoidi
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
FR2843124B1 (fr) 2002-08-02 2004-10-15 Goemar Lab Sa Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
DK2216318T3 (en) * 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
US20040166130A1 (en) 2002-12-23 2004-08-26 L'oreal Lanolin-free cosmetic composition comprising a hydroxylated fatty acid aromatic ester
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same

Also Published As

Publication number Publication date
EA010802B1 (ru) 2008-12-30
AU2005306320B2 (en) 2011-09-08
KR20070090928A (ko) 2007-09-06
AU2005306320A1 (en) 2006-05-26
US7884131B2 (en) 2011-02-08
CN101102988A (zh) 2008-01-09
EP1824809A2 (en) 2007-08-29
EA200701100A1 (ru) 2007-10-26
JP2008520739A (ja) 2008-06-19
IL183246A0 (en) 2007-08-19
US20110178047A1 (en) 2011-07-21
WO2006055965A3 (en) 2006-11-30
EP1824809A4 (en) 2010-03-03
MX2007006049A (es) 2007-07-24
CN101102988B (zh) 2011-12-14
CA2588166A1 (en) 2006-05-26
US20060241088A1 (en) 2006-10-26
NZ555394A (en) 2010-07-30
WO2006055965A2 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
BRPI0516803A (pt) oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
WO2008036353A3 (en) Omega-3 diglyceride emulsions
NO20090692L (no) Farmasoytiske og kostholdsprodukter som omfatter vitamin K2
ES521523A0 (es) Procedimiento para la preparacion de una composicion lipidica para alimentacion oral, enteral o parenteral.
SE8405308D0 (sv) Farmaceutisk komposition och forfarande for framstellning av densamma
BR0311324A (pt) Dessaturases de ácidos graxos de fungos
ATE430794T1 (de) Öl, das langkettige, mehrfach ungesättigte fettsäuren aus biomassen enthält, verfahren zur herstellung, lebensmittel, nahrungsmittelzusammensetzung, kosmetische oder pharmazeutische zusammensetzung, die dieses enthält
EA201000400A1 (ru) Твердые жировые композиции, содержащие полиненасыщенные жирные кислоты, и способы их получения и использования
BR0106178A (pt) Processo para produção de ésteres de ácidos graxos de esteróis dietéticos
WO2004101757A3 (en) Production of polyunsaturated fatty acids in oleaginous yeasts
ATE542892T1 (de) Delta-17-desaturasen und ihre verwendung bei der herstellung von mehrfach ungesättigten fettsäuren
PT996732E (pt) Metodos e composicoes para sintese de acidos gordos polinsaturados de cadeia longa em plantas
ATE545702T1 (de) Delta-5-desaturase und ihre verwendung bei der herstellung von mehrfach ungesättigten fettsäuren
BRPI0413786A (pt) ácido graxo dessaturases de primula
EA200970238A1 (ru) ПРИМЕНЕНИЕ МАСЕЛ С DPA(n-6) В ДЕТСКОМ ПИТАНИИ
ATE544858T1 (de) Delta-5-desaturase und ihre verwendung bei der herstellung von mehrfach ungesättigten fettsäuren
RU2018110375A (ru) Композиции из рафинированного масла и способы их изготовления
EP2506848A4 (en) SUBSTANCES TO REDUCE THE IMPACT OF HARD CARDIAL EVENTS CONTAINING AN EXTRACT OF RED FERMENTED RICE AND A MULTIPLE UNSATURATED OMEGA-3 FATTY ACID OR DERIVATIVES THEREOF
ATE311113T1 (de) Palmitoleinsäure und ihre verwendung in lebensmitteln
WO2003059875A3 (en) DERIVATIVES OF α-PHENYLTHIOCARBOXYLIC AND α-PHENYLOXY-CARBOXYLIC ACIDS USEFUL FOR THE TREATMENT OF DISEASES RESPONDING TO PPARα ACTIVATION
ATE424732T1 (de) Zubereitungen enthaltend mehrfach ungesättigte phospholipide, monoterpene und tryptophan und/oder phytol-derivate
DE69918177D1 (de) Polymerisationsverfahren durch dielektrische heizung von ungesättigten fettsäuren, von estern von ungesättigten fettsäuren, von ungesättigten kohlenwasserstoffen oder von ungesättigten derivaten dieser produkte
WO2006111633A3 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
SE0201566D0 (sv) New composition
CN105886492A (zh) 一种固定化脂肪酶及其制备方法和在催化合成甘油酯型pufa中的应用

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.